Literature DB >> 20160456

Neuroinflammation - an early event in both the history and pathogenesis of Alzheimer's disease.

Piet Eikelenboom1, Erik van Exel, Jeroen J M Hoozemans, Rob Veerhuis, Annemieke J M Rozemuller, Willem A van Gool.   

Abstract

BACKGROUND: About hundred years ago, Oskar Fischer proposed that the senile plaques are the consequence of the deposition of a foreign substance that could induce an inflammatory response leading to an abnormal neuritic response of the surrounding neurons.
OBJECTIVES: To show that the interest in inflammation in Alzheimer's disease (AD) is not only an early event in the history of AD but that inflammation is also an early event in the pathogenesis of AD.
METHODS: Evaluation of the neuropathological, epidemiological and genetic evidence for a role of inflammation early in the pathogenesis of AD.
RESULTS: Neuropathological studies show presence of activated microglia and inflammation-related mediators in the cerebral neocortex of autopsied patients with a low Braak stage for AD pathology. Prospective population-based cohort studies indicate that higher serum levels of acute phase proteins predict dementia. On a genetic level, it was found that the production capacity of proinflammatory cytokines after stimulation with lipopolysaccharide (a process that is under strong genetic control) is higher in offspring with a parental history of late-onset AD.
CONCLUSION: Neuropathological studies show that a neuroinflammatory response in the cerebral neocortex parallels the early stages of AD pathology and precedes the late stage, tau-related pathology. Epidemiological and genetic studies indicate that systemic markers of the innate immunity are risk factors for late-onset AD. Copyright 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20160456     DOI: 10.1159/000283480

Source DB:  PubMed          Journal:  Neurodegener Dis        ISSN: 1660-2854            Impact factor:   2.977


  103 in total

1.  Lipolysaccharide-Induced Neuroinflammation Is Associated with Alzheimer-Like Amyloidogenic Axonal Pathology and Dendritic Degeneration in Rats.

Authors:  Xiaohua Deng; Meili Li; Weiming Ai; Lixin He; Dahua Lu; Peter R Patrylo; Huaibin Cai; Xuegang Luo; Zhiyuan Li; Xiaoxin Yan
Journal:  Adv Alzheimer Dis       Date:  2014-06

2.  Arginine deprivation and immune suppression in a mouse model of Alzheimer's disease.

Authors:  Matthew J Kan; Jennifer E Lee; Joan G Wilson; Angela L Everhart; Candice M Brown; Andrew N Hoofnagle; Marilyn Jansen; Michael P Vitek; Michael D Gunn; Carol A Colton
Journal:  J Neurosci       Date:  2015-04-15       Impact factor: 6.167

Review 3.  Brain metabolic dysfunction at the core of Alzheimer's disease.

Authors:  Suzanne M de la Monte; Ming Tong
Journal:  Biochem Pharmacol       Date:  2013-12-28       Impact factor: 5.858

Review 4.  Progressive inflammation-mediated neurodegeneration after traumatic brain or spinal cord injury.

Authors:  Alan I Faden; Junfang Wu; Bogdan A Stoica; David J Loane
Journal:  Br J Pharmacol       Date:  2015-06-12       Impact factor: 8.739

5.  Sinomenine inhibits microglial activation by Aβ and confers neuroprotection.

Authors:  Shilpa Mishra Shukla; Shiv K Sharma
Journal:  J Neuroinflammation       Date:  2011-09-14       Impact factor: 8.322

6.  IL-33 is induced by amyloid-β stimulation and regulates inflammatory cytokine production in retinal pigment epithelium cells.

Authors:  Xiao-Cui Liu; Xiao-Fei Liu; Cong-Xiang Jian; Chen-Jun Li; Shou-Zhi He
Journal:  Inflammation       Date:  2012-04       Impact factor: 4.092

7.  Paeonol Suppresses Neuroinflammatory Responses in LPS-Activated Microglia Cells.

Authors:  Li Xia He; Xiaoyun Tong; Jing Zeng; Yuanqing Tu; Saicun Wu; Manping Li; Huaming Deng; Miaomiao Zhu; Xiucun Li; Hong Nie; Li Yang; Feng Huang
Journal:  Inflammation       Date:  2016-12       Impact factor: 4.092

8.  Pathological Hallmarks, Clinical Parallels, and Value for Drug Testing in Alzheimer's Disease of the APP[V717I] London Transgenic Mouse Model.

Authors:  An Tanghe; Annelies Termont; Pascal Merchiers; Stephan Schilling; Hans-Ulrich Demuth; Louise Scrocchi; Fred Van Leuven; Gerard Griffioen; Tom Van Dooren
Journal:  Int J Alzheimers Dis       Date:  2010-09-02

9.  Variant of TREM2 associated with the risk of Alzheimer's disease.

Authors:  Thorlakur Jonsson; Hreinn Stefansson; Stacy Steinberg; Ingileif Jonsdottir; Palmi V Jonsson; Jon Snaedal; Sigurbjorn Bjornsson; Johanna Huttenlocher; Allan I Levey; James J Lah; Dan Rujescu; Harald Hampel; Ina Giegling; Ole A Andreassen; Knut Engedal; Ingun Ulstein; Srdjan Djurovic; Carla Ibrahim-Verbaas; Albert Hofman; M Arfan Ikram; Cornelia M van Duijn; Unnur Thorsteinsdottir; Augustine Kong; Kari Stefansson
Journal:  N Engl J Med       Date:  2012-11-14       Impact factor: 91.245

10.  A combination cocktail improves spatial attention in a canine model of human aging and Alzheimer's disease.

Authors:  Elizabeth Head; Heather L Murphey; Amy L S Dowling; Katie L McCarty; Samuel R Bethel; Jonathan A Nitz; Melanie Pleiss; Jenna Vanrooyen; Mike Grossheim; Jeffery R Smiley; M Paul Murphy; Tina L Beckett; Dieter Pagani; Frederick Bresch; Curt Hendrix
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.